Growth hormone and hexarelin prevent endothelial vasodilator dysfunction in aortic rings of the hypophysectomized rat

Journal of Cardiovascular Pharmacology

Volumn 34, Issue 3, 1999, Pages 454-460

  Rossoni, Giuseppe ^a   Locatelli, Vittorio ^a   De Gennaro Colonna, Vito ^a   Torsello, Antonio ^a   Schweiger, Francesca ^a   Boghen, Muny ^b   Nilsson, Magnus ^b   Bernareggi, Micaela ^a   Müller, Eugenio Edoardo ^a   Berti, Ferruccio ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Pharmacia & Upjohn AB   (Sweden)

Author keywords

Acetylcholine; Aortic rings; Endothelin 1; Growth hormone; Hexarelin; Hypophysectomy; Vascular endothelium dysfunction

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; ACETYLCHOLINE; ENDOTHELIN 1; GROWTH HORMONE; HEXARELIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTERY DILATATION; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; HORMONE ACTION; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HYPOPHYSECTOMY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; VASCULAR ENDOTHELIUM; VASCULAR RING;

6-KETOPROSTAGLANDIN F1 ALPHA; ACETYLCHOLINE; ANIMALS; AORTA; BODY WEIGHT; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; HOMEOSTASIS; HUMAN GROWTH HORMONE; HUMANS; HYPOPHYSECTOMY; MALE; OLIGOPEPTIDES; OMEGA-N-METHYLARGININE; PROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; VASODILATION;

EID: 0032864669     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199909000-00021     Document Type: Article

References (24)

1. De Gennaro Colonna V, Rossoni G, Bonacci D, et al. Worsening of ischemic damage in hearts from rats with selective growth hormone deficiency. Eur J Pharmacol 1996;314:333-8.
2. De Gennaro Colonna V, Rossoni G, Bernareggi M, Müller EE, Berti F. Cardiac ischemia and impairment of vascular endothelium function in hearts from GH-deficient rats: protection by hexarelin. Eur J Pharmacol 1997;334:201-7.
3. De Gennaro Colonna V, Rossoni G, et al. Hexarelin, a growth hormone-releasing peptide, discloses protectant activity against cardiovascular damage in rats with isolated growth hormone deficiency. Cardiologia 1997;42:1165-72.
4. Cooke JP, Tsao PS. Endothelium-derived relaxing factor: an overview. In: Sowers JR, ed. Endocrinology of the vasculature. Totowa, NJ: Humana Press, 1996:3-19.
5. Schalen DS, Reichlin S. Plasma growth hormone concentration in the rat determined by radioimmunoassay: influence of sex, pregnancy, lactation, anaesthesia, hypophysectomy and extracellular pituitary transplants. Endocrinology 1966;79:275-80.
6. Breier HB, Gallaher BW, Gluckman PD. Radioimmunoassay for insulin-like growth factor-I: solutions to some potential problems and pitfalls. J Endocrinol 1991;128:347-57.
7. D'Ercole AJ, Sties AD, Underwood LE. Tissue concentration of somatomedin C: further evidence for multiple sites of synthesis and paracrine or autocrine mechanism of action. Proc Natl Acad Sci U S A 1984;81:935-9.
8. Pradelles P, Grassi J, Maclouf J. Enzyme immunoassay of eicosanoids using acetylcholine esterase as label: an alternative to radioimmunoassay. Anal Chem 1985;57:1170-3.
9. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991;43:109-42.
10. Berti F, Rossoni G, Della Bella D, et al. Nitric oxide and prostacyclin influence coronary vasomotor tone in perfused rabbit heart and modulate endothelin-1 activity. J Cardiovasc Pharmacol 1993;22:321-6.
11. Förstermann U. Phospholipid metabolism and EDRF production. In: Ryan US, Rubanyi GM, eds. Endothelial regulation of vascular tone. New York: Marcel Dekker, 1992:125-36.
12. Perdue JF. Chemistry, structure and function of insulin-like growth factors and their receptors: a review. Can J Biochem Cell Biol 1984;62:1237-18.
13. Hirschberg R, Kopple JD. Evidence that insulin-like growth factor I increases renal plasma flow and glomerular filtration rate in fasted rats. J Clin Invest 1989;83:326-30.
14. Guler HP, Eckardt KU, Zapp J, Bauer C, Froesch ER. Insulin-like growth factor I increases glomerular filtration rate and renal plasma flow in man. Acta Endocrinol 1989;121:101-6.
15. Haylor J, Singh I, El-Nahas AM. Nitric oxide synthesis inhibitor prevents vasodilation by insulin-like growth factor 1. Kidney Int 1991;39:333-5.
16. Bar RS, Boes M, Drake BL, Booth BA, Henley SA, Sandra A. Insulin, insulin-like growth factors and vascular endothelium. Am J Med 1988;85:59-70.
17. Tsukahara H, Gordienko DV, Toushoff B, Gelato MC, Goligorsky MS. Direct demonstration of insulin-like growth factor-I-induced nitric oxide production by endothelial cells. Kidney Int 1994;45: 598-604.
18. Böger RH, Skamira C, Bode-Böger SM, Brabant G, von zur Muhlen A, Frolich JC. Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. J Clin Invest 1996;98:2706-13.
19. Batchelor BR, Penner J, Hirsch J, Stern JS. Effects of hypophysectomy and acute growth hormone treatment upon glucose metabolism in adipose tissues and isolated adipocytes of rats. Horm Metab Res 1976;8:24-33.
20. Folkow B, Isaksson OG, Karlstrom G, Lever AF, Nordlander M. Trophic effects of hypophyseal hormones on resistance vessels and the heart in normotensive and renal hypertensive rats. Acta Physiol Scand 1992;144:291-306.
21. Elam MB, Wilcox HG, Solomon SS, Heimberg M. In vivo growth hormone treatment stimulates secretion of very low density lipoprotein by the isolated perfused rat liver. Endocrinology 1992;131: 2717-22.
22. th Annual Meeting of the Endocrine Society, Minneapolis, 1997:153 (abstract).
23. th Annual Meeting of the Endocrine Society, New Orleans, 1998:302 (abstract).
24. 2+-free medium. J Pharmacol Exp Ther 1983;226:258-68.